Exclusive: Philippines defied experts' advice in pursuing dengue immunization programMANILA (Reuters) - As she announced in January 2016 that the Philippines would immunize one million children with a new dengue vaccine, the nation s then health secretary Janette Garin boasted it was a world-first and a tribute to her country s  expertise  in research. At the time, it seemed the Philippines could be on the cusp of a breakthrough to combat a potentially lethal tropical virus that had been endemic in large parts of the Southeast Asian nation for decades. Almost two years later, the program lies in tatters and has been suspended after Sanofi Pasteur, a division of French drug firm Sanofi, said at the end of last month the vaccine itself may in some cases increase the risk of severe dengue in recipients not previously infected by the virus. Documents reviewed by Reuters that have not been disclosed until now, as well as interviews with local experts, show that key recommendations made by a Philippines Department of Health (DOH) advisory body of doctors and pharmacologists were not heeded before the program was rolled out to 830,000 children. After Garin s announcement, the Formulary Executive Council (FEC) of advisers urged caution over the vaccine because it said its safety and cost-effectiveness had not been established. After twice meeting in January, the panel approved the state s purchase of the vaccine on Feb 1, 2016 but recommended stringent conditions, minutes of all three meetings show.  Based on the available scientific evidence presented to the Council, there is still a need to establish long-term safety, effectiveness and cost-effectiveness,  the FEC told Garin in a  letter on that day. The letter was reviewed by Reuters. The FEC said Dengvaxia should be introduced through small-scale pilot tests and phased implementation rather than across three regions in the country at the same time, and only after a detailed  baseline  study of the prevalence and strains of dengue in the targeted area, the FEC letter and minutes of the meetings said. The experts also recommended that Dengvaxia be bought in small batches so the price could be negotiated down. An economic evaluation report commissioned by Garin s own department had found the proposed cost of 1,000 pesos ($21.29) per dose was  not cost-effective  from a public payer perspective, the minutes from the meetings reveal.   For reasons that Reuters was unable to determine, these recommendations were ignored. The DOH purchased 3 million doses of Dengvaxia in one lot, enough for the required three vaccinations for each child in the proposed immunization program and paid 1,000 pesos per dose, a copy of the purchase order reviewed by Reuters shows. It did conduct a  limited baseline study  in late February and March 2016, but the survey looked at  common illnesses  rather than the prevalence of dengue, according to guidelines issued by Garin s office at the time and reviewed by Reuters. Garin, who was part of the government of former president Benigno Aquino and replaced when President Rodrigo Duterte took power in June, 2016, did not respond to requests for comment on why she ignored the local experts  recommendations. A physician, Garin has defended her conduct and a program that she said was  implemented in accordance with WHO guidance and recommendations .  I understand the concern,  she told Philippine TV station ABS-CBN on Friday.  Even us, we re also very angry when we learned about Sanofi s announcement about severe dengue. I m also a mother. My child was also vaccinated. I was also vaccinated.  DOH spokesman Lyndon Lee Suy also did not respond to text messages or questions emailed to him. Sanofi Philippines declined comment on the Philippines government decision. However, Dr. Su-Peing Ng, Global Medical Head of Sanofi Pasteur, told Reuters:  We communicated all known benefits and risks of the vaccine to the Philippines government.   Rontgene Solante, former president of the Philippines Society for Microbiology and Infectious Diseases, said health officials were motivated to end the debilitating impact of dengue on the Philippines, where there are about 200,000 reported cases each year and many more unreported. Over 1,000 people died of the disease in the country last year. Two months after the FEC wrote to the health secretary, the DOH began immunizing one million students around the age of 10 in all three target areas in April 2016, in accordance with its original plan but at odds with the FEC s recommendations to conduct a slow roll-out of the vaccine.   The usual process for the DOH that has protected our children for so many decades was not followed. That s a fact,  said Susan Mercado, a former Philippines health department undersecretary and former senior official at the World Health Organization (WHO). WHO said in April 2016 that the Philippines  campaign appeared to meet its criteria for using Dengvaxia because the targeted regions had high levels of dengue exposure; the vaccine would be provided to children 9 years and older; and they would each receive three doses. WHO was not involved in the deliberations of the FEC, according to the minutes. It said in a statement last week that a position paper on the dengue vaccine it published in July 2016 did not include a recommendation for countries to introduce it.  Now, after Sanofi s warnings, WHO has said it agrees with the government s decision to suspend the immunization program. The current secretary of health in the Duterte administration, Francisco Duque, said he would carry out a  thorough analysis  of the FEC s recommendations and the program before passing judgment. He said the Council s recommendations were not legally enforceable.  At the end of the day, the final decision is made by (the)secretary of health,  he told Reuters.  But because of the expertise that the members of the FEC have, it is something that you don t want to ignore.  Underpinning the concerns in 2016 about Dengvaxia, since confirmed by Sanofi, were fears that the vaccine would act like a primary infection for those who had never had dengue. If they were bitten by a mosquito carrying the virus after the vaccination, it could be akin to getting dengue a second time, which often leads to far more severe symptoms and potentially death if bad cases are not treated quickly. The concerns were first raised by noted U.S.-based tropical disease expert, Dr. Scott Halstead, who urged both Sanofi and the WHO to proceed with caution. In the Philippines, Dr. Antonio Dans, an epidemiologist from the University of the Philippines, led a delegation of physicians to the DOH in March 2016 where, citing Halstead s research, they pressed for the campaign to be aborted.  The data was not definitive but it was clear there were uncertainties and risks. Why not wait for the complete studies to be finished before endangering so many children?  Dans told  Reuters. In a Senate hearing late last year, Garin said she was aware of Halstead s assessment but dismissed it.  This is a theory ... it has not been proven,  she said at the time. Two sources involved in the program said no antibody testing was undertaken, as recommended by the FEC.  Antibody testing, while not 100 percent accurate, indicates whether an individual has had dengue before. Duque, the current health secretary, is demanding the company refund the 3 billion pesos ($60 million) paid for the vaccinations and has threatened legal action against Sanofi if it is proven to have withheld information. A criminal probe is underway into how a danger to public health came about and two Congressional inquiries have been convened in the Philippines. Duque told Reuters he was concerned that the program was paid from an  off-budget  allocation, meaning it bypassed Congressional scrutiny. Reuters was unable to confirm this. Until now, one child out of the 830,000 vaccinated, a girl who was hospitalized with severe dengue, has been linked definitively by the DOH to the campaign. But the department of health says it still does not have complete data on those who fell ill after taking Dengvaxia. worldnews
exclusive philippines defied experts advice pursuing dengue immunization programmanila reuters as announced january philippines would immune one million children new dengue vaccine nation health secretary gazette gain boasted tribute country expertise research at time seemed philippines could cusp breakthrough combat potentially lethal tropical virus endemic large parts southeast asian nation decades almost two years later program lies matters suspended sankei poster division french drug firm sankei said end last month vaccine may cases increase risk severe dengue recipients previously infected virus documents reviewed reuters disclosed well interviews local experts show key recommendations made philippines department health doh advisory body doctors pharmacologists needed program rolled children after gain announcement formula executive council fec advisers urged caution vaccine said safety established after twice meeting january panel approved state purchase vaccine feb recommended stringent conditions minutes three meetings show based available scientific evidence presented council still need establish safety effectiveness fec told gain letter day the letter reviewed reuters the fec said dengvaxia introduced pilot tests phased implementation rather across three regions country time detailed baseline study prevalence strains dengue targeted area fec letter minutes meetings said the experts also recommended dengvaxia bought small batches price could negotiated an economic evaluation report commissioned gain department found proposed cost pesos per dose public payer perspective minutes meetings reveal for reasons reuters unable determine recommendations ignored the doh purchased million doses dengvaxia one lot enough required three vaccination child proposed immunization program paid pesos per dose copy purchase order reviewed reuters shows it conduct limited baseline study late february march survey looked common illnesses rather prevalence dengue according guidelines issued gain office time reviewed reuters gain part government former president benign amino replaced president rodrigo duterte took power june respond requests comment ignored local experts recommendations a physician gain defended conduct program said implemented accordance who guidance recommendations i understand concern told philippine tv station friday even us also angry learned sankei announcement severe dengue i also mother my child also fascinated i also fascinated doh spokesman london lee sup also respond text messages questions emailed sankei philippines declined comment philippines government decision however ng global medical head sankei poster told reuters we communicated known benefits risks vaccine philippines government rontgene slate former president philippines society microbiology infectious diseases said health officials motivated end debilitating impact dengue philippines reported cases year many reported over people died disease country last year two months fec wrote health secretary doh began immunizing one million students around age three target areas april accordance original plan odds fec recommendations conduct slow vaccine the usual process doh protected children many decades followed that fact said susan mercado former philippines health department undersecretary former senior official world health organization who who said april philippines campaign appeared meet criteria using dengvaxia targeted regions high levels dengue exposure vaccine would provided children years older would receive three doses who involved deliberations fec according minutes it said statement last week position paper dengue vaccine published july include recommendation countries introduce now sankei warnings who said agrees government decision suspend immunization program the current secretary health duterte administration francisco due said would carry thorough analysis fec recommendations program passing judgment he said council recommendations legally enforceable at end day final decision made secretary health told reuters but expertise members fec something want ignore undermining concerns dengvaxia since confirmed sankei fears vaccine would act like primary infection never dengue if bitten mosquito carrying virus vaccination could akin getting dengue second time often leads far severe symptoms potentially death bad cases treated quickly the concerns first raised noted tropical disease expert scott halted urged sankei who proceed caution in philippines antonio dans epidemiologist university philippines led delegation physicians doh march citing halted research pressed campaign aborted the data definitive clear uncertainties risks why wait complete studies finished endangering many children dans told reuters in senate hearing late last year gain said aware halted assessment dismissed this theory proven said time two sources involved program said antibody testing undertaken recommended fec antibody testing percent accurate indicates whether individual dengue due current health secretary demanding company refund billion pesos million paid vaccination threatened legal action sankei proven withheld information a criminal probe underway danger public health came two congressional inquiries convened philippines due told reuters concerned program paid allocation meaning bypassed congressional scrutiny reuters unable confirm until one child fascinated girl hospitalized severe dengue linked definitively doh campaign but department health says still complete data fell ill taking dengvaxia worldnews
Your task is to classify the provided input as real or fake news. Label 0 is meant for fake news, Label 1 is for real news. TEXT: Exclusive: Philippines defied experts' advice in pursuing dengue immunization programMANILA (Reuters) - As she announced in January 2016 that the Philippines would immunize one million children with a new dengue vaccine, the nation s then health secretary Janette Garin boasted it was a world-first and a tribute to her country s  expertise  in research. At the time, it seemed the Philippines could be on the cusp of a breakthrough to combat a potentially lethal tropical virus that had been endemic in large parts of the Southeast Asian nation for decades. Almost two years later, the program lies in tatters and has been suspended after Sanofi Pasteur, a division of French drug firm Sanofi, said at the end of last month the vaccine itself may in some cases increase the risk of severe dengue in recipients not previously infected by the virus. Documents reviewed by Reuters that have not been disclosed until now, as well as interviews with local experts, show that key recommendations made by a Philippines Department of Health (DOH) advisory body of doctors and pharmacologists were not heeded before the program was rolled out to 830,000 children. After Garin s announcement, the Formulary Executive Council (FEC) of advisers urged caution over the vaccine because it said its safety and cost-effectiveness had not been established. After twice meeting in January, the panel approved the state s purchase of the vaccine on Feb 1, 2016 but recommended stringent conditions, minutes of all three meetings show.  Based on the available scientific evidence presented to the Council, there is still a need to establish long-term safety, effectiveness and cost-effectiveness,  the FEC told Garin in a  letter on that day. The letter was reviewed by Reuters. The FEC said Dengvaxia should be introduced through small-scale pilot tests and phased implementation rather than across three regions in the country at the same time, and only after a detailed  baseline  study of the prevalence and strains of dengue in the targeted area, the FEC letter and minutes of the meetings said. The experts also recommended that Dengvaxia be bought in small batches so the price could be negotiated down. An economic evaluation report commissioned by Garin s own department had found the proposed cost of 1,000 pesos ($21.29) per dose was  not cost-effective  from a public payer perspective, the minutes from the meetings reveal.   For reasons that Reuters was unable to determine, these recommendations were ignored. The DOH purchased 3 million doses of Dengvaxia in one lot, enough for the required three vaccinations for each child in the proposed immunization program and paid 1,000 pesos per dose, a copy of the purchase order reviewed by Reuters shows. It did conduct a  limited baseline study  in late February and March 2016, but the survey looked at  common illnesses  rather than the prevalence of dengue, according to guidelines issued by Garin s office at the time and reviewed by Reuters. Garin, who was part of the government of former president Benigno Aquino and replaced when President Rodrigo Duterte took power in June, 2016, did not respond to requests for comment on why she ignored the local experts  recommendations. A physician, Garin has defended her conduct and a program that she said was  implemented in accordance with WHO guidance and recommendations .  I understand the concern,  she told Philippine TV station ABS-CBN on Friday.  Even us, we re also very angry when we learned about Sanofi s announcement about severe dengue. I m also a mother. My child was also vaccinated. I was also vaccinated.  DOH spokesman Lyndon Lee Suy also did not respond to text messages or questions emailed to him. Sanofi Philippines declined comment on the Philippines government decision. However, Dr. Su-Peing Ng, Global Medical Head of Sanofi Pasteur, told Reuters:  We communicated all known benefits and risks of the vaccine to the Philippines government.   Rontgene Solante, former president of the Philippines Society for Microbiology and Infectious Diseases, said health officials were motivated to end the debilitating impact of dengue on the Philippines, where there are about 200,000 reported cases each year and many more unreported. Over 1,000 people died of the disease in the country last year. Two months after the FEC wrote to the health secretary, the DOH began immunizing one million students around the age of 10 in all three target areas in April 2016, in accordance with its original plan but at odds with the FEC s recommendations to conduct a slow roll-out of the vaccine.   The usual process for the DOH that has protected our children for so many decades was not followed. That s a fact,  said Susan Mercado, a former Philippines health department undersecretary and former senior official at the World Health Organization (WHO). WHO said in April 2016 that the Philippines  campaign appeared to meet its criteria for using Dengvaxia because the targeted regions had high levels of dengue exposure; the vaccine would be provided to children 9 years and older; and they would each receive three doses. WHO was not involved in the deliberations of the FEC, according to the minutes. It said in a statement last week that a position paper on the dengue vaccine it published in July 2016 did not include a recommendation for countries to introduce it.  Now, after Sanofi s warnings, WHO has said it agrees with the government s decision to suspend the immunization program. The current secretary of health in the Duterte administration, Francisco Duque, said he would carry out a  thorough analysis  of the FEC s recommendations and the program before passing judgment. He said the Council s recommendations were not legally enforceable.  At the end of the day, the final decision is made by (the)secretary of health,  he told Reuters.  But because of the expertise that the members of the FEC have, it is something that you don t want to ignore.  Underpinning the concerns in 2016 about Dengvaxia, since confirmed by Sanofi, were fears that the vaccine would act like a primary infection for those who had never had dengue. If they were bitten by a mosquito carrying the virus after the vaccination, it could be akin to getting dengue a second time, which often leads to far more severe symptoms and potentially death if bad cases are not treated quickly. The concerns were first raised by noted U.S.-based tropical disease expert, Dr. Scott Halstead, who urged both Sanofi and the WHO to proceed with caution. In the Philippines, Dr. Antonio Dans, an epidemiologist from the University of the Philippines, led a delegation of physicians to the DOH in March 2016 where, citing Halstead s research, they pressed for the campaign to be aborted.  The data was not definitive but it was clear there were uncertainties and risks. Why not wait for the complete studies to be finished before endangering so many children?  Dans told  Reuters. In a Senate hearing late last year, Garin said she was aware of Halstead s assessment but dismissed it.  This is a theory ... it has not been proven,  she said at the time. Two sources involved in the program said no antibody testing was undertaken, as recommended by the FEC.  Antibody testing, while not 100 percent accurate, indicates whether an individual has had dengue before. Duque, the current health secretary, is demanding the company refund the 3 billion pesos ($60 million) paid for the vaccinations and has threatened legal action against Sanofi if it is proven to have withheld information. A criminal probe is underway into how a danger to public health came about and two Congressional inquiries have been convened in the Philippines. Duque told Reuters he was concerned that the program was paid from an  off-budget  allocation, meaning it bypassed Congressional scrutiny. Reuters was unable to confirm this. Until now, one child out of the 830,000 vaccinated, a girl who was hospitalized with severe dengue, has been linked definitively by the DOH to the campaign. But the department of health says it still does not have complete data on those who fell ill after taking Dengvaxia. worldnews
Your task is to classify the provided input as real or fake news. Label 0 is meant for fake news, Label 1 is for real news. TEXT: exclusive philippines defied experts advice pursuing dengue immunization programmanila reuters as announced january philippines would immune one million children new dengue vaccine nation health secretary gazette gain boasted tribute country expertise research at time seemed philippines could cusp breakthrough combat potentially lethal tropical virus endemic large parts southeast asian nation decades almost two years later program lies matters suspended sankei poster division french drug firm sankei said end last month vaccine may cases increase risk severe dengue recipients previously infected virus documents reviewed reuters disclosed well interviews local experts show key recommendations made philippines department health doh advisory body doctors pharmacologists needed program rolled children after gain announcement formula executive council fec advisers urged caution vaccine said safety established after twice meeting january panel approved state purchase vaccine feb recommended stringent conditions minutes three meetings show based available scientific evidence presented council still need establish safety effectiveness fec told gain letter day the letter reviewed reuters the fec said dengvaxia introduced pilot tests phased implementation rather across three regions country time detailed baseline study prevalence strains dengue targeted area fec letter minutes meetings said the experts also recommended dengvaxia bought small batches price could negotiated an economic evaluation report commissioned gain department found proposed cost pesos per dose public payer perspective minutes meetings reveal for reasons reuters unable determine recommendations ignored the doh purchased million doses dengvaxia one lot enough required three vaccination child proposed immunization program paid pesos per dose copy purchase order reviewed reuters shows it conduct limited baseline study late february march survey looked common illnesses rather prevalence dengue according guidelines issued gain office time reviewed reuters gain part government former president benign amino replaced president rodrigo duterte took power june respond requests comment ignored local experts recommendations a physician gain defended conduct program said implemented accordance who guidance recommendations i understand concern told philippine tv station friday even us also angry learned sankei announcement severe dengue i also mother my child also fascinated i also fascinated doh spokesman london lee sup also respond text messages questions emailed sankei philippines declined comment philippines government decision however ng global medical head sankei poster told reuters we communicated known benefits risks vaccine philippines government rontgene slate former president philippines society microbiology infectious diseases said health officials motivated end debilitating impact dengue philippines reported cases year many reported over people died disease country last year two months fec wrote health secretary doh began immunizing one million students around age three target areas april accordance original plan odds fec recommendations conduct slow vaccine the usual process doh protected children many decades followed that fact said susan mercado former philippines health department undersecretary former senior official world health organization who who said april philippines campaign appeared meet criteria using dengvaxia targeted regions high levels dengue exposure vaccine would provided children years older would receive three doses who involved deliberations fec according minutes it said statement last week position paper dengue vaccine published july include recommendation countries introduce now sankei warnings who said agrees government decision suspend immunization program the current secretary health duterte administration francisco due said would carry thorough analysis fec recommendations program passing judgment he said council recommendations legally enforceable at end day final decision made secretary health told reuters but expertise members fec something want ignore undermining concerns dengvaxia since confirmed sankei fears vaccine would act like primary infection never dengue if bitten mosquito carrying virus vaccination could akin getting dengue second time often leads far severe symptoms potentially death bad cases treated quickly the concerns first raised noted tropical disease expert scott halted urged sankei who proceed caution in philippines antonio dans epidemiologist university philippines led delegation physicians doh march citing halted research pressed campaign aborted the data definitive clear uncertainties risks why wait complete studies finished endangering many children dans told reuters in senate hearing late last year gain said aware halted assessment dismissed this theory proven said time two sources involved program said antibody testing undertaken recommended fec antibody testing percent accurate indicates whether individual dengue due current health secretary demanding company refund billion pesos million paid vaccination threatened legal action sankei proven withheld information a criminal probe underway danger public health came two congressional inquiries convened philippines due told reuters concerned program paid allocation meaning bypassed congressional scrutiny reuters unable confirm until one child fascinated girl hospitalized severe dengue linked definitively doh campaign but department health says still complete data fell ill taking dengvaxia worldnews